TB-500 & BPC-157
$ 140.00
Experience Enhanced Healing with TB-500 & BPC-157
Harness the healing power of TB-500 and BPC-157 to accelerate recovery and get back to your peak performance. Order now and experience the synergistic benefits of this peptide duo.
Half-life:
- Approximately 10 days
Possible Dosage & Cycle Length:
- Injury Healing Protocol:
- Men/Women: 400-800 mcg per day
100% Canadian Made
FREE Shipping on orders over $199 or more
Canada Post XPressPost Shipping
-
Description
-
Reviews (0)
TB-500 & BPC-157 (10MG) – Peptide Duo for Enhanced Healing and Recovery
Product Overview: Experience the power of two potent peptides combined to accelerate healing and enhance recovery. TB-500, also known as Thymosin Beta-4, and BPC-157, or Body Protection Compound-157, work synergistically to promote tissue repair, reduce inflammation, and support overall recovery from injuries.
Key Benefits:
- Accelerated Healing: TB-500 and BPC-157 work together to stimulate the repair of damaged tissues, including muscles, tendons, and ligaments, leading to faster recovery times.
- Reduced Inflammation: BPC-157 has anti-inflammatory properties, helping to decrease inflammation at the site of injury, while TB-500 enhances tissue regeneration.
- Enhanced Recovery: By promoting cell migration and blood vessel formation, these peptides support the body’s natural healing processes, resulting in improved recovery outcomes.
- Joint and Tendon Support: BPC-157 may provide additional support for joint and tendon health, reducing pain and discomfort associated with injuries.
Half-life:
- Approximately 10 days
Possible Dosage & Cycle Length:
- Injury Healing Protocol:
- Men/Women: 400-800 mcg per day
- Administer the daily dosage via site-specific injections until the injury has healed completely.
Safety and Quality Assurance: Our TB-500 and BPC-157 peptides are produced under strict quality control standards to ensure purity, potency, and safety. Consult with a healthcare professional before starting any new peptide regimen.
There are no reviews yet.